This antibody was developed against Recombinant Protein corresponding to amino acids:RQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVPDPE
Specificity of antibody verified on a Protein Array containing target protein plus 383 other non-specific proteins.
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
FAQs for COX-2 Antibody (NBP1-85499). (Showing 1 - 1 of 1 FAQs).
I am a student researching COX-2 expression in felines and am looking for a suitable primary antibody to use in IHC. To your knowledge, have any of your COX-2 antibodies been used successfully with feline COX-2? If yes, I would be very interested in learning more. If not, would it be possible to run a sequence homology of feline COX-2 (GenBank ABM65700.1, accession EF036473.1) against your available COX-2 antibodies to determine the overlap and likelihood of cross-reactivity?
We have not tested any of these antibodies for their reactivity in felines. However, we do have a number of antibodies that look like they may cross-react with feline. NBP1-85499 recognizes a region that is about 90-91% similar to feline COX2. NBP2-04015 recognizes a region in humans that is 94% similar to feline COX2. NB100-868 recognizes a region in humans at the far C-terminal 12 amino acids that is 100% identical to feline COX2. NBP1-19354 recognizes a region that is also about 95% similar to feline COX2. Only NBP1-85499 and NBP1-19354 have been tested for use in IHC. If you would like to test this antibody in an untested species and/or application and share your results with us, then I can recommend our Innovators Reward Program.
Inhibitor kappa B-alpha (IkappaB-alpha) The transcription factor nuclear factor kappa beta (NFkB) is highly regulated by triggers such as stress, free-radicals, UV light, and hypoxia. NFkB is one of the fastest responding transcription factors in humans. The NFKB signaling pathway is ess... Read full blog post.